Published in Biochemistry on January 04, 2013
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
Viral hepatitis C. Lancet (2003) 5.81
Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol (1999) 4.37
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A (1999) 3.77
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure (1999) 3.04
Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol (2002) 2.61
A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology (2001) 2.21
Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc Natl Acad Sci U S A (1992) 2.18
A comparison of viral RNA-dependent RNA polymerases. Curr Opin Struct Biol (2005) 2.14
MASCOT: multiple alignment system for protein sequences based on three-way dynamic programming. Comput Appl Biosci (1993) 1.97
Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem (2005) 1.87
Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology (1998) 1.81
Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J Virol (2002) 1.72
Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J Mol Biol (2003) 1.65
Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem (2005) 1.54
Retracted Oligomeric interaction of hepatitis C virus NS5B is critical for catalytic activity of RNA-dependent RNA polymerase. J Biol Chem (2001) 1.51
An overview of HCV molecular biology, replication and immune responses. Virol J (2011) 1.37
Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs (2007) 1.18
Modulation of hepatitis C virus RNA-dependent RNA polymerase activity by structure-based site-directed mutagenesis. J Biol Chem (2002) 1.18
Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor. Antimicrob Agents Chemother (2006) 1.14
The nucleotide-binding site of human sphingosine kinase 1. J Biol Chem (2002) 1.14
Selection of 3'-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymerase. J Virol (2002) 1.13
A relaxed discrimination of 2'-O-methyl-GTP relative to GTP between de novo and Elongative RNA synthesis by the hepatitis C RNA-dependent RNA polymerase NS5B. J Biol Chem (2004) 1.13
Adenosine derivatives for dehydrogenases and kinases. Methods Enzymol (1977) 1.08
Biochemical and pre-steady-state kinetic characterization of the hepatitis C virus RNA polymerase (NS5BDelta21, HC-J4). Biochemistry (2006) 1.06
Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol (2001) 1.01
Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase. J Biol Chem (2003) 1.01
Regulation of de novo-initiated RNA synthesis in hepatitis C virus RNA-dependent RNA polymerase by intermolecular interactions. J Virol (2010) 1.01
Characterization of the metal ion binding properties of the hepatitis C virus RNA polymerase. J Biol Chem (2002) 0.98
Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology (2001) 0.97
Development of the system ensuring a high-level expression of hepatitis C virus nonstructural NS5B and NS5A proteins. Protein Expr Purif (2006) 0.97
Recombinant viral RdRps can initiate RNA synthesis from circular templates. RNA (2005) 0.93
Affinity labeling of a tyrosine residue in the ATP binding site of the recA protein from Escherichia coli with 5'-p-fluorosulfonylbenzoyladenosine. J Biol Chem (1985) 0.92
High resolution footprinting of the hepatitis C virus polymerase NS5B in complex with RNA. J Biol Chem (2007) 0.91
Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther Adv Chronic Dis (2011) 0.91
ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10). J Biol Chem (1996) 0.91
Affinity labeling of Escherichia coli DNA polymerase I by 5'-fluorosulfonylbenzoyladenosine. Identification of the domain essential for polymerization and Arg-682 as the site of reactivity. J Biol Chem (1988) 0.90
Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends. Future Med Chem (2009) 0.87
Mapping cooperative activity of the hepatitis C virus RNA-dependent RNA polymerase using genotype 1a-1b chimeras. Biochem Biophys Res Commun (2004) 0.82
The involvement of serine and carboxyl groups in the activity of bovine pancreatic deoxyribonuclease A. J Biol Chem (1974) 0.81
Affinity labelling of smooth-muscle myosin light-chain kinase with 5'-[p-(fluorosulphonyl)benzoyl]adenosine. Biochem J (1993) 0.81
Lysine and tyrosine in the NADH inhibitory site of bovine liver glutamate dehydrogenase. J Biol Chem (1981) 0.80
The ATP-binding site of brain phosphatidylinositol 4-kinase PI4K230 as revealed by 5'-p-fluorosulfonylbenzoyladenosine. Int J Biochem Cell Biol (2001) 0.79
Inactivation of isocitrate dehydrogenase kinase/phosphatase by 5'-[p-(fluorosulfonyl)benzoyl]adenosine is not due to the labeling of the invariant lysine residue found in the protein kinase family. Eur J Biochem (1998) 0.77
Mapping of the ATP-binding domain of human fructosamine 3-kinase-related protein by affinity labelling with 5'-[p-(fluorosulfonyl)benzoyl]adenosine. Biochem J (2008) 0.77
Template primer-dependent binding of 5'-fluorosulfonyl-benzoyldeoxyadenosine by Escherichia coli DNA polymerase I. Identification of arginine 682 as the binding site and its implication in catalysis. J Biol Chem (1990) 0.76
Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem (2009) 1.45
Identification of cellular factors associated with the 3'-nontranslated region of the hepatitis C virus genome. Mol Cell Proteomics (2006) 1.21
Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol (2002) 1.03
Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol (2010) 1.01
The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J Virol (2008) 0.98
Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucleic Acids Res (2005) 0.98
Identification and evaluation of anti hepatitis C virus phytochemicals from Eclipta alba. J Ethnopharmacol (2012) 0.97
Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity. Antimicrob Agents Chemother (2011) 0.91
A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties. Virology (2005) 0.90
A peptide nucleic acid-neamine conjugate that targets and cleaves HIV-1 TAR RNA inhibits viral replication. J Med Chem (2004) 0.89
Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome. Virology (2007) 0.89
Single acute-dose and repeat-doses toxicity of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice. Oligonucleotides (2008) 0.88
Affinity capture and identification of host cell factors associated with hepatitis C virus (+) strand subgenomic RNA. Mol Cell Proteomics (2013) 0.88
Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem (2002) 0.87
Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog. Antiviral Res (2002) 0.86
Mechanism of RNA cleavage catalyzed by sequence specific polyamide nucleic acid-neamine conjugate. Oligonucleotides (2007) 0.86
STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends. Mol Cancer Ther (2008) 0.86
A Bioinformatics Resource for TWEAK-Fn14 Signaling Pathway. J Signal Transduct (2012) 0.84
Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket. Biochemistry (2002) 0.83
PNA targeting the PBS and A-loop sequences of HIV-1 genome destabilizes packaged tRNA3(Lys) in the virions and inhibits HIV-1 replication. Virology (2002) 0.83
An efficient biodelivery system for antisense polyamide nucleic acid (PNA). Oligonucleotides (2008) 0.82
Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome. Oligonucleotides (2008) 0.81
A single deletion at position 134, 135, or 136 in the beta 7-beta 8 loop of the p51 subunit of HIV-1 RT disrupts the formation of heterodimeric enzyme. J Cell Biochem (2010) 0.81
A positively charged side chain at position 154 on the beta8-alphaE loop of HIV-1 RT is required for stable ternary complex formation. Nucleic Acids Res (2003) 0.79
Impact of template overhang-binding region of HIV-1 RT on the binding and orientation of the duplex region of the template-primer. Mol Cell Biochem (2009) 0.78
The glutamine side chain at position 91 on the β5a-β5b loop of human immunodeficiency virus type 1 reverse transcriptase is required for stabilizing the dNTP binding pocket. Biochemistry (2011) 0.77
Inhibition of HIV Replication by Cyclic and Hairpin PNAs Targeting the HIV-1 TAR RNA Loop. J Nucleic Acids (2012) 0.77
Influence of the RNase H domain of retroviral reverse transcriptases on the metal specificity and substrate selection of their polymerase domains. Virol J (2009) 0.76
Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots. Int J Curr Chem (2011) 0.75